Co-Diagnostics, Inc. (CODX)
Largest Insider Buys in Sector
CODX Stock Price History Chart
CODX Stock Performance
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for …
Insider Activity of Co-Diagnostics, Inc.
Over the last 12 months, insiders at Co-Diagnostics, Inc. have bought $0 and sold $0 worth of Co-Diagnostics, Inc. stock.
On average, over the past 5 years, insiders at Co-Diagnostics, Inc. have bought $5,697 and sold $5.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,000 shares for transaction amount of $5,697 was made by Brown Brian Lee (Chief Financial Officer) on 2023‑03‑20.
List of Insider Buy and Sell Transactions, Co-Diagnostics, Inc.
| 2023-03-20 | Chief Financial Officer | 3,000 0.0095% | $1.90 | $5,697 | -36.32% | |||
| 2021-09-08 | Sale | director | 2,000 0.007% | $10.46 | $20,910 | -37.92% | ||
| 2021-05-19 | Sale | General Counsel | 108,334 0.3747% | $8.53 | $923,628 | -1.52% | ||
| 2021-01-15 | Sale | Chief Executive Officer | 38,046 0.1385% | $11.00 | $418,506 | -13.05% | ||
| 2021-01-14 | Sale | director | 10,000 0.0353% | $10.29 | $102,900 | -9.74% | ||
| 2021-01-13 | Sale | director | 21,000 0.0734% | $10.09 | $211,890 | -8.44% | ||
| 2021-01-13 | Sale | director | 25,000 0.0877% | $10.13 | $253,262 | -8.44% | ||
| 2020-12-14 | Sale | director | 34,000 0.1206% | $10.10 | $343,400 | -11.77% | ||
| 2020-12-10 | Sale | director | 20,000 0.0726% | $10.15 | $203,000 | -9.03% | ||
| 2020-11-25 | Sale | CFO and Secretary | 179,048 0.5796% | $10.50 | $1.88M | -20.35% | ||
| 2020-11-24 | Sale | Chief Executive Officer | 89,528 0.3335% | $10.51 | $940,939 | -8.38% | ||
| 2020-11-23 | Sale | Chief Executive Officer | 143,138 0.5331% | $10.44 | $1.49M | -7.67% | ||
| 2020-11-20 | Sale | Chief Executive Officer | 36,034 0.1349% | $11.09 | $399,617 | -12.53% | ||
| 2020-05-28 | Sale | director | 42,500 0.159% | $18.02 | $766,050 | -23.13% | ||
| 2020-05-26 | Sale | director | 25,000 0.0917% | $18.24 | $456,000 | -25.35% | ||
| 2020-05-20 | Sale | director | 50,000 0.1769% | $18.14 | $906,750 | -26.84% | ||
| 2020-05-19 | Sale | director | 50,000 0.1779% | $18.50 | $925,000 | -27.86% | ||
| 2018-05-11 | Chief Science Officer | 2,610 0.0209% | $1.82 | $4,750 | +21.58% | |||
| 2018-05-03 | Chief Science Officer | 1,000 0.0081% | $1.91 | $1,910 | +16.96% | |||
| 2018-04-23 | Chief Science Officer | 1,000 0.0083% | $2.02 | $2,020 | +12.83% |
Insider Historical Profitability
| Satterfield Brent | Chief Science Officer | 2275000 7.125% | $0.77 | 5 | 0 | +18.15% |
| Brown Brian Lee | Chief Financial Officer | 76236 0.2388% | $0.77 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $2M | 5.7 | 1.78M | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $672,000.00 | 1.92 | 600,400 | -2.69% | -$18,579.61 | <0.01 | |
| BlackRock | $560,056.00 | 1.6 | 500,050 | -0.35% | -$1,993.60 | <0.0001 | |
| Geode Capital Management | $329,842.00 | 0.94 | 294,422 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $305,648.00 | 0.87 | 272,900 | 0% | +$0 | <0.01 |